Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A southwest oncology group study

S. E. Jones, P. N. Grozea, Thomas P Miller, E. J. Van Slyck, S. P. Balcerzak, J. J. Costanzi, F. S. Morrison, H. J. Eyre, C. J. Fabian, L. Dabich

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Between 1977 and 1983 the Southwest Oncology Group (SWOG) evaluated chemotherapy alone (cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP) or chemoimmunotherapy (CHOP-levamisole or CHOP-levamisole-BCG) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma (ML). Of 281 evaluable patients with favorable histologic types of ML, 171 (61%) achieved complete remission (CR) and there was no difference in CR rate, CR duration, or survival according to the type of initial treatment. Of 388 evaluable patients with unfavorable histologic types of ML, 194 (50%) achieved CR. Levamisole appeared to adversely affect CR rates in nodular mixed and nudular large-cell lymphoma and CR duration in patients with unfavorable histology ML. Chemoimmunotherapy with levamisole or levamisole-BCG offers no advantage in terms of CR rates, CR duration, or survival compared to CHOP chemotherapy alone, and levamisole may have had an adverse impact on outcome in certain subtypes of ML.

Original languageEnglish (US)
Pages (from-to)1318-1324
Number of pages7
JournalJournal of Clinical Oncology
Volume3
Issue number10
StatePublished - 1985
Externally publishedYes

Fingerprint

Levamisole
Vincristine
Mycobacterium bovis
Prednisone
Doxorubicin
Cyclophosphamide
Lymphoma
Drug Therapy
Survival
Histology
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma : A southwest oncology group study. / Jones, S. E.; Grozea, P. N.; Miller, Thomas P; Van Slyck, E. J.; Balcerzak, S. P.; Costanzi, J. J.; Morrison, F. S.; Eyre, H. J.; Fabian, C. J.; Dabich, L.

In: Journal of Clinical Oncology, Vol. 3, No. 10, 1985, p. 1318-1324.

Research output: Contribution to journalArticle

Jones, SE, Grozea, PN, Miller, TP, Van Slyck, EJ, Balcerzak, SP, Costanzi, JJ, Morrison, FS, Eyre, HJ, Fabian, CJ & Dabich, L 1985, 'Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A southwest oncology group study', Journal of Clinical Oncology, vol. 3, no. 10, pp. 1318-1324.
Jones, S. E. ; Grozea, P. N. ; Miller, Thomas P ; Van Slyck, E. J. ; Balcerzak, S. P. ; Costanzi, J. J. ; Morrison, F. S. ; Eyre, H. J. ; Fabian, C. J. ; Dabich, L. / Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma : A southwest oncology group study. In: Journal of Clinical Oncology. 1985 ; Vol. 3, No. 10. pp. 1318-1324.
@article{67c4c62ebc60436a91ae9fc20f84ff4a,
title = "Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A southwest oncology group study",
abstract = "Between 1977 and 1983 the Southwest Oncology Group (SWOG) evaluated chemotherapy alone (cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP) or chemoimmunotherapy (CHOP-levamisole or CHOP-levamisole-BCG) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma (ML). Of 281 evaluable patients with favorable histologic types of ML, 171 (61{\%}) achieved complete remission (CR) and there was no difference in CR rate, CR duration, or survival according to the type of initial treatment. Of 388 evaluable patients with unfavorable histologic types of ML, 194 (50{\%}) achieved CR. Levamisole appeared to adversely affect CR rates in nodular mixed and nudular large-cell lymphoma and CR duration in patients with unfavorable histology ML. Chemoimmunotherapy with levamisole or levamisole-BCG offers no advantage in terms of CR rates, CR duration, or survival compared to CHOP chemotherapy alone, and levamisole may have had an adverse impact on outcome in certain subtypes of ML.",
author = "Jones, {S. E.} and Grozea, {P. N.} and Miller, {Thomas P} and {Van Slyck}, {E. J.} and Balcerzak, {S. P.} and Costanzi, {J. J.} and Morrison, {F. S.} and Eyre, {H. J.} and Fabian, {C. J.} and L. Dabich",
year = "1985",
language = "English (US)",
volume = "3",
pages = "1318--1324",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma

T2 - A southwest oncology group study

AU - Jones, S. E.

AU - Grozea, P. N.

AU - Miller, Thomas P

AU - Van Slyck, E. J.

AU - Balcerzak, S. P.

AU - Costanzi, J. J.

AU - Morrison, F. S.

AU - Eyre, H. J.

AU - Fabian, C. J.

AU - Dabich, L.

PY - 1985

Y1 - 1985

N2 - Between 1977 and 1983 the Southwest Oncology Group (SWOG) evaluated chemotherapy alone (cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP) or chemoimmunotherapy (CHOP-levamisole or CHOP-levamisole-BCG) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma (ML). Of 281 evaluable patients with favorable histologic types of ML, 171 (61%) achieved complete remission (CR) and there was no difference in CR rate, CR duration, or survival according to the type of initial treatment. Of 388 evaluable patients with unfavorable histologic types of ML, 194 (50%) achieved CR. Levamisole appeared to adversely affect CR rates in nodular mixed and nudular large-cell lymphoma and CR duration in patients with unfavorable histology ML. Chemoimmunotherapy with levamisole or levamisole-BCG offers no advantage in terms of CR rates, CR duration, or survival compared to CHOP chemotherapy alone, and levamisole may have had an adverse impact on outcome in certain subtypes of ML.

AB - Between 1977 and 1983 the Southwest Oncology Group (SWOG) evaluated chemotherapy alone (cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP) or chemoimmunotherapy (CHOP-levamisole or CHOP-levamisole-BCG) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma (ML). Of 281 evaluable patients with favorable histologic types of ML, 171 (61%) achieved complete remission (CR) and there was no difference in CR rate, CR duration, or survival according to the type of initial treatment. Of 388 evaluable patients with unfavorable histologic types of ML, 194 (50%) achieved CR. Levamisole appeared to adversely affect CR rates in nodular mixed and nudular large-cell lymphoma and CR duration in patients with unfavorable histology ML. Chemoimmunotherapy with levamisole or levamisole-BCG offers no advantage in terms of CR rates, CR duration, or survival compared to CHOP chemotherapy alone, and levamisole may have had an adverse impact on outcome in certain subtypes of ML.

UR - http://www.scopus.com/inward/record.url?scp=0021971630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021971630&partnerID=8YFLogxK

M3 - Article

C2 - 3900301

AN - SCOPUS:0021971630

VL - 3

SP - 1318

EP - 1324

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -